Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

PURPOSE: Nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, has demonstrated improved survival over docetaxel in previously treated advanced non–small-cell lung cancer (NSCLC). First-line monotherapy with nivolumab for advanced NSCLC was evaluated in the phase I, multicohor...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Gettinger, Scott, Rizvi, Naiyer A., Chow, Laura Q., Borghaei, Hossein, Brahmer, Julie, Ready, Neal, Gerber, David E., Shepherd, Frances A., Antonia, Scott, Goldman, Jonathan W., Juergens, Rosalyn A., Laurie, Scott A., Nathan, Faith E., Shen, Yun, Harbison, Christopher T., Hellmann, Matthew D.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2016
Soggetti:
ORIGINAL REPORTS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5569692/
https://ncbi.nlm.nih.gov/pubmed/27354485
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.66.9929
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi